<DOC>
	<DOCNO>NCT00073112</DOCNO>
	<brief_summary>The purpose study determine ABT-751 decrease tumor , determine long tumor shrinkage maintain patient renal cell cancer . Patients receive ABT-751 mouth daily 21 day . Patients drug 7 day start next cycle drug .</brief_summary>
	<brief_title>A Study ABT-751 Patients With Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion Criteria Renal Cell Carcinoma . Recurrent tumor . At least 6 week postnephrectomy . Able tolerate normal activity daily live . Adequate bone marrow , kidney , liver function . Exclusion Criteria Pregnant breast feeding . Antitumor therapy within 4 week start ABT751 administration . CNS metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>